The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE Journal Article


Authors: Lisi, L.; McGuire, S.; Sharp, A.; Chiosis, G.; Navarra, P.; Feinstein, D. L.; Dello Russo, C.
Article Title: The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE
Abstract: Ansamycins are very effective HSP90 inhibitors that showed significant beneficial effects in the treatment of EAE. However, their toxicity and poor stability in solution limit their clinical use. In the present study we have characterized the anti-inflammatory properties of a novel HSP90 inhibitor, PU-H71, and tested its effects in EAE. Our findings show that PU-H71 reduced lipopolysaccharide astrocyte activation but failed to reduce the inflammatory cytokine activation. In contrast to ansamycins, PU-H71 weakly affects EAE clinical course. In conclusion, although PU-H71 displayed some anti-inflammatory properties, it appeared in vivo less effective than the more toxic HSP90 inhibitors. © 2012 Elsevier B.V.
Keywords: astrocytes; microglia; pu-h71; hsp90 inhibitors; eae; glial activation
Journal Title: Journal of Neuroimmunology
Volume: 255
Issue: 1-2
ISSN: 0165-5728
Publisher: Elsevier Inc.  
Date Published: 2013-02-15
Start Page: 1
End Page: 7
Language: English
DOI: 10.1016/j.jneuroim.2012.10.008
PROVIDER: scopus
PUBMED: 23123171
PMCID: PMC3710720
DOI/URL:
Notes: --- - "Export Date: 1 February 2013" - "CODEN: JNRID" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gabriela Chiosis
    279 Chiosis